Hims与诺和诺德的对决；辉瑞月度GLP-1数据发布；第四季度财报汇总；及其他动态
The Hims vs. Novo showdown; Pfizer’s monthly GLP-1 data; Q4 earnings roundup; and more
生命科学资讯
生物技术与制药领域的最新动态
美国呼吁司法部调查Hims公司涉及GLP-1药物问题
US calls for DOJ investigation of Hims over GLP-1 drugs
特朗普处方药计划启动遇冷，部分人指其普及性不足。
TrumpRx launch falls flat for some, citing generic access
美国卫生与公众服务部放弃对受阻的340B折扣试点计划的法律诉讼。
HHS drops legal fight over blocked 340B rebate pilot
美国支出法案中的孤儿药调整将减轻FDA负担
Orphan drug tweak in US spending bill will make life easier for the FDA
Agomab与SpyGlass创下2021年以来生物科技IPO最大周纪录
Agomab, SpyGlass cap biggest week for biotech IPOs since 2021
百健CEO表示阿尔茨海默病药物Leqembi有望持续增长。
Biogen CEO says Alzheimer's drug Leqembi on track for continued growth
UniQure暂停法布里病研究高剂量组；Aro公布庞贝病数据。
UniQure pauses higher doses in Fabry study; Aro shares Pompe data
杰夫·麦克多诺为NodThera的NLRP3制定宏伟计划；第一三共Enhertu负责人卸任
Geoff McDonough's big plans for NodThera's NLRP3; Enhertu leader steps down at Daiichi
Roivant分拆公司Priovant公布brepocitinib治疗皮肤结节病的二期临床试验数据
Roivant spinout Priovant touts Phase 2 brepocitinib data in cutaneous sarcoidosis
事后直播：深度解析诺和诺德与Hims的GLP-1药物对决
Post-Hoc Live: Analyzing the Novo vs. Hims GLP-1 showdown
Illumina押注医疗健康领域，因特朗普政府削减NIH资金引发行业变局。
Illumina bets on healthcare after Trump administration's NIH funding disruptions
Illumina押注医疗保健客户，因NIH资金中断后寻求新增长点
Illumina bets on healthcare customers after NIH funding disruptions - Endpoints News
FDA局长马卡里质疑Hims公司复合韦戈维药丸计划。
FDA chief Makary takes aim at Hims' compounded Wegovy pill plans
诺和诺德就Wegovy药片起诉Hims面临法律障碍。
Novo's threat to sue Hims over Wegovy pill faces legal hurdle
白宫计划周四推出特朗普处方药计划
White House plans to launch TrumpRx Thursday
Veradermics首席执行官喜迎IPO首日股价飙升122%
Veradermics CEO has a great hair day with 122% pop in IPO
#ISC26：拜耳asundexian在III期试验中将缺血性中风风险降低26%
#ISC26: Bayer’s asundexian reduced ischemic strokes by 26% in Phase 3 trial
百时美施贵宝管线进展引关注，多项数据即将揭晓。
Bristol Myers draws pipeline excitement as several data readouts near
GLP-1药物与超级碗
GLP-1s and the Super Bowl